181 related articles for article (PubMed ID: 29596904)
21. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
Rubenstein JL; Geng H; Fraser EJ; Formaker P; Chen L; Sharma J; Killea P; Choi K; Ventura J; Kurhanewicz J; Lowell C; Hwang J; Treseler P; Sneed PK; Li J; Wang X; Chen N; Gangoiti J; Munster PN; Damato B
Blood Adv; 2018 Jul; 2(13):1595-1607. PubMed ID: 29986852
[TBL] [Abstract][Full Text] [Related]
22. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
Trnĕný M; Verhoef G; Dyer MJ; Ben Yehuda D; Patti C; Canales M; Lopez A; Awan FT; Montgomery PG; Janikova A; Barbui AM; Sulek K; Terol MJ; Radford J; Guidetti A; Di Nicola M; Siraudin L; Hatteville L; Schwab S; Oprea C; Gianni AM
Haematologica; 2018 Aug; 103(8):1351-1358. PubMed ID: 29748443
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type.
Savini P; Lanzi A; Foschi FG; Marano G; Stefanini GF
Ann Hematol; 2014 Feb; 93(2):333-4. PubMed ID: 23680870
[No Abstract] [Full Text] [Related]
25. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
26. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
28. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
29. Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type.
Lee WJ; Won KH; Won CH; Chang SE; Choi JH; Moon KC; Park CS; Huh J; Suh C; Lee MW
Acta Derm Venereol; 2016 Feb; 96(2):245-50. PubMed ID: 26014205
[TBL] [Abstract][Full Text] [Related]
30. Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.
Tomuleasa C; Iluta S; Pasca S; Roman A; Piciu D; Jitaru C; Teodorescu P; Rus I; Bojan A; Dima D; Zdrenghea M; Petrushev B
Int J Hematol; 2020 Oct; 112(4):597-598. PubMed ID: 32886277
[No Abstract] [Full Text] [Related]
31. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
Park C; Lee HS; Kang KW; Lee WS; Do YR; Kwak JY; Shin HJ; Kim SY; Yi JH; Lim SN; Lee JO; Yang DH; Jang H; Choi B; Lim J; Sun CH; Byun JM; Yoon SS; Koh Y
Nat Commun; 2024 Mar; 15(1):2776. PubMed ID: 38555311
[TBL] [Abstract][Full Text] [Related]
32. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Ishida T; Fujiwara H; Nosaka K; Taira N; Abe Y; Imaizumi Y; Moriuchi Y; Jo T; Ishizawa K; Tobinai K; Tsukasaki K; Ito S; Yoshimitsu M; Otsuka M; Ogura M; Midorikawa S; Ruiz W; Ohtsu T
J Clin Oncol; 2016 Dec; 34(34):4086-4093. PubMed ID: 27621400
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: An Indian perspective.
Lakshmaiah KC; Rachan Shetty KS; Sathyanarayanan V; Lokanatha D; Abraham LJ; Babu KG
J Cancer Res Ther; 2015; 11(4):857-61. PubMed ID: 26881531
[TBL] [Abstract][Full Text] [Related]
35. Atypical clinicopathologic presentation of primary cutaneous diffuse large B-cell lymphoma, leg type.
Massone C; Fink-Puches R; Wolf I; Zalaudek I; Cerroni L
J Am Acad Dermatol; 2015 Jun; 72(6):1016-20. PubMed ID: 25824272
[TBL] [Abstract][Full Text] [Related]
36. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.
Pham-Ledard A; Prochazkova-Carlotti M; Andrique L; Cappellen D; Vergier B; Martinez F; Grange F; Petrella T; Beylot-Barry M; Merlio JP
Mod Pathol; 2014 Mar; 27(3):402-11. PubMed ID: 24030746
[TBL] [Abstract][Full Text] [Related]
37. Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
Kiesewetter B; Lamm W; Neuper O; Mayerhoefer ME; Simonitsch-Klupp I; Raderer M
Hematol Oncol; 2019 Oct; 37(4):345-351. PubMed ID: 31283840
[TBL] [Abstract][Full Text] [Related]
38. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
[TBL] [Abstract][Full Text] [Related]
40. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
